ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 855,20
1,08%
Dow Jones
44 156,73
0,30%
DAX
21 303,82
1,25%
Brent Oil
78,335
0,00%
Bitcoin
103 406,62
-0,21%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Calliditas Therapeutics AB (CALT)

  7. Calliditas Therapeutics AB (CALT) Actualités

CALT

Calliditas Therapeutics AB (CALT)

Calliditas Therapeutics AB
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CALT
DateHeureSourceTitreSymboleSociété
23/09/202422h44Edgar (US Regulatory)Form 15F-12B - Securities registration termination of foreign private issuers [Section 12(b)]NASDAQ:CALTCalliditas Therapeutics AB
16/09/202415h46PR Newswire (US)Delisting of Calliditas Therapeutics AB (publ) from Nasdaq StockholmNASDAQ:CALTCalliditas Therapeutics AB
03/09/202413h13PR Newswire (US)Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)NASDAQ:CALTCalliditas Therapeutics AB
03/09/202412h33PR Newswire (US)Calliditas Therapeutics takes certain corporate actions following announcement by Asahi KaseiNASDAQ:CALTCalliditas Therapeutics AB
13/08/202407h25PR Newswire (US)Calliditas Interim Report January to June 2024NASDAQ:CALTCalliditas Therapeutics AB
05/08/202407h26PR Newswire (US)Invitation to the presentation of Calliditas´s interim report January - June 2024NASDAQ:CALTCalliditas Therapeutics AB
01/08/202415h00GlobeNewswire Inc.Calliditas Therapeutics to Attend 2024 Women in Nephrology (WIN) Leadership ConferenceNASDAQ:CALTCalliditas Therapeutics AB
31/07/202414h23PR Newswire (US)Number of shares and votes in Calliditas TherapeuticsNASDAQ:CALTCalliditas Therapeutics AB
26/07/202422h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CALTCalliditas Therapeutics AB
26/07/202417h23PR Newswire (US)Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA NephropathyNASDAQ:CALTCalliditas Therapeutics AB
26/07/202408h29PR Newswire (US)Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitisNASDAQ:CALTCalliditas Therapeutics AB
04/07/202409h44PR Newswire (US)Launch of Phase 3 clinical trial with Nefecon in JapanNASDAQ:CALTCalliditas Therapeutics AB
18/06/202412h25PR Newswire (US)Calliditas provides setanaxib patent updateNASDAQ:CALTCalliditas Therapeutics AB
17/06/202418h01PR Newswire (US)Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)NASDAQ:CALTCalliditas Therapeutics AB
30/05/202420h20PR Newswire (US)Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathyNASDAQ:CALTCalliditas Therapeutics AB
28/05/202414h46PR Newswire (US)Calliditas Therapeutics Presents Data at the 61st European Renal Association CongressNASDAQ:CALTCalliditas Therapeutics AB
28/05/202414h09Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:CALTCalliditas Therapeutics AB
28/05/202409h17PR Newswire (US)Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei CorporationNASDAQ:CALTCalliditas Therapeutics AB
23/05/202407h55PR Newswire (US)Calliditas Q1 report, January - March 2024NASDAQ:CALTCalliditas Therapeutics AB
16/05/202408h45PR Newswire (US)Invitation to the presentation of Calliditas´s interim report January - March 2024NASDAQ:CALTCalliditas Therapeutics AB
15/05/202414h30PR Newswire (US)Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in StockholmNASDAQ:CALTCalliditas Therapeutics AB
15/05/202413h36PR Newswire (US)Notice of annual general meeting of Calliditas Therapeutics AB (publ)NASDAQ:CALTCalliditas Therapeutics AB
14/05/202413h52PR Newswire (US)Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in ChinaNASDAQ:CALTCalliditas Therapeutics AB
06/05/202408h16PR Newswire (US)Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibNASDAQ:CALTCalliditas Therapeutics AB
24/04/202419h35PR Newswire (US)Calliditas Therapeutics' 2023 Annual Report PublishedNASDAQ:CALTCalliditas Therapeutics AB
24/04/202409h30PR Newswire (US)Calliditas Announces Positive NefIgArd Open Label Extension ResultsNASDAQ:CALTCalliditas Therapeutics AB
18/04/202413h13PR Newswire (US)Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024NASDAQ:CALTCalliditas Therapeutics AB
09/04/202413h24PR Newswire (US)Calliditas Therapeutics to Attend Conferences in AprilNASDAQ:CALTCalliditas Therapeutics AB
08/04/202414h38PR Newswire (US)Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos AiresNASDAQ:CALTCalliditas Therapeutics AB
08/04/202409h24PR Newswire (US)Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatmentNASDAQ:CALTCalliditas Therapeutics AB
 Showing the most relevant articles for your search:NASDAQ:CALT

Dernières Valeurs Consultées

EU
BN
Danone
EU
RI
Pernod Ricard
EU
BEL20
Bel 20
EU
DG
Vinci
COIN
AVAXUSD
Avalanche
EU
ML
Michelin
USI
USTECH100
US Tech 100
EU
PX4
SBF 120
EU
EN
Bouygues
COIN
ETHUSD
Ethereum
NASDAQ
MSFT
Microsoft
NASDAQ
NVDA
NVIDIA
COIN
ADAUSD
Cardano
SPI
SP500
S&P 500
EU
SGO
Cie de SaintGobain
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés